Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research[1].
Motavizumab shows activity after F protein initiates interaction with the cell membrane and before virus transcription[2].
Motavizumab inhibits F protein-mediated cell-to-cell fusion[2].
Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice[1].
| Animal Model: | Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2[1] |
| Dosage: | 1.25 mg in 0.1 ml of PBS/per mouse |
| Administration: | Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once |
| Result: | Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5. Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice. |
[1]. MejÍas A, et al. Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model. Virol J. 2007 Oct 25;4:109.
[2]. Huang K, et al. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol. 2010 Aug;84(16):8132-40.